Saturday, August 8, 2015

Now You, We Can Prevent Type 2 Diabetes Complication

More and More doctors are recommending the early treatment and management of Type 2 Diabetes Mellitus (T2DM) for us to avoid complication like heart disease and kidney diseases.

Now there will be a comprehensive solutions for T2DM patients. Early treatment with much deeper understanding on how we can solve it, that includes lifestyle modifications alongside with pharmacological treatment. Drug therapy and lifestyle chane is the key in preventing the development of more health risk.


“The risk of developing further complications such as kidney and cardiovascular disease increases when type 2 diabetes is not properly managed from the onset. We’ve come to realize that the ill effects of diabetes on patients can be minimized with aggressive treatment early on. Because type 2 diabetes can lead to heart attack and strokes, timely, comprehensive, and consistent intervention is hugely important.”

 - Dr. Bobby Mirasol, Former President of Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM) & ASEAN Federation of Endocrine Societies (AFES). 

Patients who has type 2 diabetes needs glycemic control through pharmacotherapy and adopting a specific ;ifestyle-related treatment.

Dapagliflozin by AstraZeneca is an oral medication who is selective and reversible inhibitor of sodium-glucose contrasporter 2 (SGLT2) who works independently insulin to help flush out excess sugar out of the body through urine removing accompanying calories.

The unique mode of action the drug offers is the first of its kind and not seen among current available treatments for type 2 diabetes in the Philippines. This is the first medicine in the new SGLT2 class to gain regulatory approval in the world, granted by the European Medicines Agency (EMA). Dapagliflozin has been subsequently approved by the US Food and Drug Administration (FDA) and is also approved in 40 countries including Australia.



Since its approval in 2014, dapagliflozin has been used to effectively treat more than 20,000 patients in the Philippines alone, with doctors citing it as an effective component of early type 2 diabetes treatment.

Doctors credit the success of dapagliflozin to its unique mechanism of action, as it addresses both pharmacological and lifestyle-related components of treatment.

For more information, visit www.astrazeneca.com

0 comments:

Post a Comment